TrialPath
Recruiting

Lung Cancer Registry

NCT04654364 · Arbeitsgemeinschaft medikamentoese Tumortherapie
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
This registry is designed as multicenter observational cohort of patients with lung cancer. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up. For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry. A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients. Data will be collected from all sites willing to participate.
Eligibility criteria
Inclusion Criteria: * stage III A-C and IV A-B NSCLC * limited disease (LD) and extensive disease (ED) SCLC) * patients ≥ 18 years Exclusion Criteria: \- Due to the non-interventional design of the registry there are no specific exclusion criteria.
Study design
Enrollment target: 500 participants
Age groups: adult, older_adult
Timeline
Starts: 2020-08-18
Estimated completion: 2030-08
Last updated: 2025-04-10
Primary outcomes
  • General characteristics (10 years)
  • Molecular testing (10 years)
  • Characterize subgroups (10 years)
Sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie · other
Contacts & investigators
ContactDaniela Wolkersdorfer · contact · office@agmt.at · +436626404412
InvestigatorRichard Greil, MD · study_chair, AGMT gemeinnützige GmbH
All locations (3)
Universitätsklinik für Innere Medizin III, PMU SalzburgRecruiting
Salzburg, State of Salzburg, Austria
Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / UniversitätsklinikenRecruiting
Innsbruck, Tyrol, Austria
Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / PneumologieRecruiting
Linz, Upper Austria, Austria
Lung Cancer Registry · TrialPath